# Berberine Cholesterol Meta-analysis: What the Evidence Says
Canonical: https://www.migaku.app/guides/berberine-cholesterol-meta-analysis-evidence-review
Category: evidence-review
Summary: Berberine Cholesterol Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are ran
Last reviewed: 2026-05-27
Reviewed by: Migaku Evidence Review
# Berberine Cholesterol Meta-analysis: What the Evidence Says

## Quick Answer

Berberine Cholesterol Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are randomized trial, so conclusions should be framed as evidence-aware guidance rather than medical advice.

## Key Takeaways

- This page is generated only from sources stored in the Migaku evidence knowledge base.
- Current evidence mix: 1 randomized trial, 1 research article.
- Claims should be interpreted with the source type, study design, population, and publication date in mind.
- This article is educational and does not replace care from a qualified clinician.

## Evidence Map

| Source | Evidence type | Level | Date | Identifier |
| --- | --- | ---: | --- | --- |
| Berberine signature and cardiometabolic diseases using randomized controlled trial, cohort study and Mendelian randomization | randomized trial | 2 | 2026-03-25 | 10.1038/s44325-026-00113-w |
| Cost-effectiveness of statins, berberine, and combination for primary cardiovascular disease prevention in Scotland | research article | 4 | 2026-04-23 | 10.1038/s44325-026-00121-w |

## What The Sources Report

- As such, it may be beneficial to use berberine combined with statins in people with hyperlipidemia, especially for those with statin intolerance or partial intolerance, and those with diabetes or at high risk of diabetes. [Zhao Jie V. (2026); evidence level 2]
- Berberine has been recommended by the International Lipid Expert Panel and the 2019 European Atherosclerosis Society/European Society of Cardiology Guidelines for the treatment of hyperlipidemia in statin-intolerant patients, however, these guidelines have not provided explicit recommendations about the use of berberine because of the lack of high-quality evidence. [Zhao Jie V. (2026); evidence level 2]
- The primary prevention of CVD through the management of dyslipidemia, a major risk factor for CVD, is a critical strategy for improving population health outcomes and reducing the associated economic impact. [Xia Yuanqing (2026); evidence level 4]
- Statin use has increased substantially in recent years, with nearly two-thirds of those taking statins for primary prevention. [Xia Yuanqing (2026); evidence level 4]

## How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

## Practical Interpretation

There is trial evidence in the current set, but population and intervention details still matter. For berberine cholesterol meta-analysis, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

## Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

## References

- Zhao Jie V. (2026). Berberine signature and cardiometabolic diseases using randomized controlled trial, cohort study and Mendelian randomization. DOI: 10.1038/s44325-026-00113-w. PMCID: PMC13018313. PMID: 41882153. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13018313/
- Xia Yuanqing (2026). Cost-effectiveness of statins, berberine, and combination for primary cardiovascular disease prevention in Scotland. DOI: 10.1038/s44325-026-00121-w. PMCID: PMC13106774. PMID: 42026133. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13106774/

## Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.